Dermatology Research and Practice最新文献

{"title":"Assessing the Psychosocial Impact of Acne Scars on Individuals With Pigmented Skin: A Multicenter Observational Study.","authors":"Marwa Majzoub, Eleonore Goubeau, Vivien Moris","doi":"10.1155/drp/6657441","DOIUrl":"10.1155/drp/6657441","url":null,"abstract":"<p><p>Acne scars, particularly in individuals with pigmented skin, can lead to significant psychosocial distress, yet the extent of this impact remains underexplored. This study aimed to assess the psychosocial effects of acne scars on patients with skin Phototypes IV-VI. This retrospective multicenter observational study involved 86 patients with acne scars who had previously consulted general practitioners. Scar severity was assessed using the Echelle d'évaluation Clinique des Cicatrices d'Acné (ECCA). Validated measures were used to evaluate psychological and quality-of-life impacts: the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms and the Dermatology Life Quality Index (DLQI) for quality of life. The study revealed that 62% of patients exhibited depressive symptoms according to the PHQ-9, and 84% reported a diminished quality of life according to the DLQI. A significant correlation was observed between acne scar severity and both psychosocial measures: ECCA and DLQI (<i>r</i> = 0.31, <i>p</i>=0.003), and ECCA and PHQ-9 (<i>r</i> = 0.27, <i>p</i>=0.010). Many participants had modified their clothing and daily activities due to their scars. The findings illustrate the profound psychosocial burden of acne scars, with a notable percentage of individuals experiencing depressive symptoms and reduced quality of life. The strong correlation between scar severity and psychosocial outcomes emphasizes the need for early, comprehensive care that addresses both dermatological and psychological aspects.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"6657441"},"PeriodicalIF":1.9,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients With Skin Cancer Prefer to Participate in Procedure Cost Discussions: A Cross-Sectional Survey.","authors":"Ritika Bhandari, Laura Rezac, Ross L Pearlman, Vinayak K Nahar, William H Black","doi":"10.1155/drp/1660527","DOIUrl":"10.1155/drp/1660527","url":null,"abstract":"<p><p>For a given skin cancer, a number of treatment options are often available. The decision of which method to use is usually made by the treating physician. Despite significant changes to the healthcare system of the United States over the past 10 years, healthcare costs continue to rise. These costs often affect patients in the form of higher deductibles, copays, and insurance premiums. The goal of this study was to determine patient attitudes regarding discussion of cost of skin cancer removal procedures and repairs. A 12-question survey was administered to 100 patients presenting for treatment of a skin cancer at an academic center. The first six questions addressed the importance the patient placed on treatment cost and related discussions, and the final six questions addressed repair cost. Greater than two-thirds of respondents felt that cost of both treatment (76%) and repair (67%) is somewhat or very important. Most patients reported that the cost of skin cancer treatment (56%) and repair (54%) should be considered by their surgeon. Furthermore, a majority of participants felt that cost differences should be discussed prior to treatment (67%) or repair (67%). Most respondents believed that cost discussion prior to treatment (64%) and repair (67%) would not affect their level of procedural anxiety. In conclusion, patients value cost discussions for treatment and repair of skin cancer. Surgeons should consider discussing these issues with patients in the appropriate clinical setting.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"1660527"},"PeriodicalIF":1.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Insights and Treatment Approaches for Dermatophytosis Affecting Vellus Hair.","authors":"Rungsima Kiratiwongwan, Charussri Leeyaphan, Pattriya Jirawattanadon, Lalita Matthapan, Waranyoo Prasong, Chatisa Panyawong, Sumanas Bunyaratavej","doi":"10.1155/drp/3373022","DOIUrl":"10.1155/drp/3373022","url":null,"abstract":"<p><p><b>Background:</b> Tinea of vellus hair is a rare condition that is recalcitrant to treatment. It is typically caused by nonanthropophilic dermatophytes. Extant data on this disease remain scarce. <b>Aims/Objectives:</b> This study aimed to delineate the clinical features and treatment outcomes of patients with tinea of vellus hair and to compare the characteristics of patients infected by anthropophilic and nonanthropophilic species. <b>Methods:</b> A 10-year retrospective study was conducted at the Department of Dermatology in a tertiary hospital in Thailand. The study included all patients with tinea of glabrous skin involving vellus hair. Baseline characteristics, clinical data, and treatment outcomes were analyzed. <b>Results:</b> Of the 31 patients in the study, two-thirds of the patients (69%) had a history of using topical medications, mainly steroids and antifungals. The face and extremities were the most common locations for lesions with positive vellus hair. There were no significant differences in data between patients infected with anthropophilic and nonanthropophilic species. Most patients received oral antifungals (80.6%). There was no significant difference in the cure rate between patients who were administered oral antifungals and those who solely utilized topical antifungals. Kaplan-Meier analysis demonstrated the overall median duration to achieve a cure was 5 weeks. <b>Conclusion:</b> The diagnosis of tinea of vellus hair should be considered in cases of tinea of the glabrous skin in exposed areas, especially in patients with a history of topical treatments. Nonanthropophilic dermatophytes are the primary causative agents of tinea of vellus hair. Systemic antifungals with prolonged duration are recommended.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"3373022"},"PeriodicalIF":1.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12463509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials\".","authors":"","doi":"10.1155/drp/9753406","DOIUrl":"https://doi.org/10.1155/drp/9753406","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2021/8382761.].</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"9753406"},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.","authors":"Saeed Bahramian, Patrick Fazeli, Arezou Rafati, Sardar Demokri, Huria Memari, Amirali Soheili, Farzad Esmaeili, Mohammad Pourmehdi Ardebili, Haniye Erfani, Seyed Mohammad Vahabi","doi":"10.1155/drp/9127126","DOIUrl":"10.1155/drp/9127126","url":null,"abstract":"<p><p><b>Objectives:</b> Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an autoinflammatory disease with a wide spectrum of manifestations and no standard treatment. Janus kinase inhibitors (JAK-I) are small-molecule drugs that affect many molecular pathways. We aim to investigate the safety and efficacy of JAK-I in the treatment of VEXAS syndrome. <b>Methods:</b> A systematic search was conducted using MeSH terms/keywords related to JAK-I and VEXAS syndrome through PubMed/Medline, Scopus, Web of Science, and Embase until July 6, 2025. <b>Results:</b> We included 29 articles: 8 cohort, 8 case series, and 13 case reports. Our study includes data for 186 cases. The mean age was 69.64 years, and 83.33% were male. The most frequent manifestations were skin lesions (64.51%), fever (64.51%), arthritis and arthralgia (61.29%), lung involvement (31.72%), and venous thrombosis (24.19%). In general, 33.87% had a complete response, and 29.57% had a partial response. Ruxolitinib was used in 117 patients. Thirty-four out of 117 (29.06%) experienced complete to partial remission. Tofacitinib was used in 31 patients. About 29% of them showed complete to partial remission. Baricitinib was used in 25 patients; 12% had complete remission, and 16% had partial remission. Upadacitinib was used in 13 patients, which led to a complete remission in 38.46%. Filgotinib was used in four patients, leading to partial remission in one case. Among all, 36.55% showed adverse effects. Of these, eight were on Ruxolitinib, two on Tofacitinib, two on Baricitinib, and three on Upadacitinib. <b>Conclusion:</b> JAK-I seems to be a promising treatment option with tolerable adverse effects for VEXAS syndrome.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"9127126"},"PeriodicalIF":1.9,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing the Differential Expression of Vitiligo Genes by Bioinformatics Methods.","authors":"Quansheng Lu, Xi He, Yao Sun, Yu Lu, Guan Jiang","doi":"10.1155/drp/6672081","DOIUrl":"10.1155/drp/6672081","url":null,"abstract":"<p><p><b>Background:</b> Vitiligo is a hypopigmentation skin disease that is easy to diagnose but difficult to treat. The etiology of vitiligo is unknown, which may be related to genetic and immune factors. <b>Objective:</b> To provide potential targets for the treatment of vitiligo through identifying signature genes based on an artificial neural network (ANN) model. <b>Methods:</b> We downloaded two publicly available datasets from GEO database and identified DEGs. We trained the random forest and ANN algorithm using training set GSE75819 to further identify new gene features and predicted the possibility of vitiligo. In addition, we further validated the performance of our model through the test set GSE53148 and verified the diagnostic value of our model with the validation set GSE53148. Finally, we used RT-qPCR to compare the expression of two genes randomly selected in this study in patients with vitiligo and healthy people. <b>Results:</b> Two genes were randomly selected from the 30 key genes identified by ANN and validated through RT-qPCR in 6 vitiligo patients. The results showed that compared with the control group, the mRNA expression of FLJ21901 in the disease group was significantly upregulated, and the mRNA expression of MAST1 was significantly downregulated, with statistical significance. <b>Conclusions:</b> Through the identification of characteristic genes and the construction of a neural network model, it was found that the differentially expressed genes can provide a new potential target for the treatment of vitiligo.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"6672081"},"PeriodicalIF":1.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12431802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Treatments for Primary Palmar Hyperhidrosis: A Systematic Review Assessing Patient-Centric Outcomes.","authors":"Foteini Moniati, Marianna Vassiliou, Christos Costa, Constantina Chatzimatthaiou, Marios Chatzimatthaiou","doi":"10.1155/drp/8867838","DOIUrl":"10.1155/drp/8867838","url":null,"abstract":"<p><p><b>Background:</b> Primary palmar hyperhidrosis (PH) is a chronic condition characterized by excessive sweating in the palms, significantly affecting the quality of life (QOL) of affected individuals. Despite the availability of various treatment modalities, the long-term efficacy and safety of these interventions remain unclear, warranting a comprehensive evaluation. This systematic review aims to assess the efficacy, safety and patient-reported outcomes of treatments for PH. <b>Methods:</b> A systematic search was conducted in PubMed, Embase and the Cochrane Library from their inception until March 2024, adhering to PRISMA guidelines. Inclusion criteria focused on prospective and retrospective studies examining PH treatments published in English. Data from eligible studies were extracted, analysed qualitatively and reported based on outcomes, including efficacy, QOL improvements and adverse effects. <b>Results:</b> Fourteen studies, including 1733 patients aged 4-77 years, were included in the final review. The treatments assessed included oral and topical oxybutynin, iontophoresis, botulinum toxin A injections, photodynamic therapy (PDT) and endoscopic thoracic sympathectomy (ETS). Oral oxybutynin demonstrated symptomatic relief in 60%-97% of the patients although anticholinergic side effects were frequently reported. ETS, while providing the highest rates of complete sweat cessation, was associated with compensatory hyperhidrosis. Noninvasive treatments like iontophoresis showed moderate efficacy with minimal side effects but required ongoing sessions for maintenance. <b>Conclusion:</b> This review highlights the efficacy of several therapeutic approaches for PH though most treatments are hindered by significant adverse effects or practical limitations. Future research should prioritize long-term studies and standardized outcome measures to guide clinical decision-making more effectively.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"8867838"},"PeriodicalIF":1.9,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing Lipid Bond Technology With Molecular Lipid Complex to Provide Lipid Treatment for Damaged Hair.","authors":"Nam Hai Lai, Thi Hong Ngoc Dang, Thu Thuy Nguyen, Duong Thuc Quyen Phan","doi":"10.1155/drp/5385312","DOIUrl":"10.1155/drp/5385312","url":null,"abstract":"<p><p>Human hair fibers are mainly composed of proteins, lipids, and water. In particular, lipids play an important role in keeping hair healthy, stabilizing its structure, affecting shine, feel, manageability, and strength. In addition to each person's physical condition and constitution, the cause of reduction and loss of hair lipids also comes from external causes such as UV, pollution, and specially styling chemicals. A decrease in hair lipid content correlates with reduced tensile strength, diminished shine, increased breakage, and hair damage. In this study, we focus on Lipid Bond Technology with small molecule real lipids derived from plant oil triglycerides, known as 369LAB Lipid Bond, reverse chemical and environmental damage by restoring lipid bonds in hair, regenerates hair structure, and improves hair strength. Research results show that 369LAB Lipid Bond has an average particle size of 39.83 nm, helping to penetrate deeply into the hair; replace lost lipids, restore lipids to damaged hair. After one use, the total amount of lipid restored is equivalent to natural hair before damage. It is nonsticky and does not clog hair follicles. SEM images show morphological improvement in the integrity of the epidermis and regeneration of lipid layers immediately, with lasting repair even after discontinuation of use. The amount of force that breaks individual hair strands in testing shows that 369LAB Lipid Bond makes hair stronger. The Lipid Bond Technology not only strengthens hair while using the product but also maintains its healthy resilience long after. The current research will provide the breakthrough for new applications in cosmetic, skin, and hair care products, to address the remaining difficulties and challenges in the treatment of damaged hair.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"5385312"},"PeriodicalIF":1.9,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Landscape of Acquired Dermal Macular Hyperpigmentation: A Bibliometric Analysis.","authors":"Abdulaziz Hamid, Kara Turner, Nada Elbuluk","doi":"10.1155/drp/8871423","DOIUrl":"10.1155/drp/8871423","url":null,"abstract":"<p><p><b>Background:</b> Acquired dermal macular hyperpigmentation (ADMH) includes lichen planus pigmentosus (LPP), ashy dermatosis (erythema dyschromicum perstans), and Riehl's melanosis (pigmented contact dermatitis/pigmented cosmetic dermatitis). The conditions that make up ADMH overlap in clinical and histopathological features. <b>Objective:</b> To conduct a bibliometric analysis to identify the top 100 most cited publications in ADMH. <b>Methods:</b> A Web of Science search was conducted on September 18, 2024, using the search terms \"lichen planus pigmentosus,\" \"ashy dermatosis,\" \"erythema dyschromicum perstans,\" \"riehl melanosis,\" \"pigmented cosmetic dermatitis,\" \"pigmented contact dermatitis,\" \"acquired dermal macular hyperpigmentation,\" or \"acquired macular pigmentation of unknown aetiology\" in the title or abstract of articles published between 1998 and 2024. The search was filtered to include articles, letters, reviews, and editorials in English. Data collected included title, author, publication year, times cited, journal of publication, affiliations, and country of origin. The top 100 most cited publications were ranked based on annual citation score. <b>Results:</b> The top 100 most cited publications consisted of 62 articles, 24 letters (i.e., letter to the editor and comments), 8 editorials, and 6 reviews published between 1998 and 2023. The most articles were published in 2018 with 14 publications. The top contributing journals were the <i>International Journal of Dermatology</i> (<i>n</i> = 15, 15%) and the <i>Journal of the European Academy of Dermatology and Venereology</i> (<i>n</i> = 14, 14%). India, South Korea, and the United States contributed the most publications (<i>n</i> = 61, 61%) on ADMH (32, 17, and 12, respectively). India also led in having the top three corresponding authors, Muthu Sendhil Kumaran (<i>n</i> = 8, 8%), Keshavamurthy Vinay (<i>n</i> = 4, 4%), and Vinod Kumar Sharma (<i>n</i> = 3, 3%). <b>Conclusion:</b> This bibliometric analysis reveals a geographical concentration in ADMH research, emphasizing the need for increased research on these conditions with more global representation in future studies.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"8871423"},"PeriodicalIF":1.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"M2 Macrophage and Extracellular Matrix Genes Are Enriched in High-Activity Lichen Planopilaris.","authors":"Ümmügülsüm Yıldız-Altay, Laura J Burns, Li-Chi Chen, Himanee Parag Dave, Mariko R Yasuda, Jillian M Richmond, Maryanne M Senna","doi":"10.1155/drp/5545886","DOIUrl":"10.1155/drp/5545886","url":null,"abstract":"<p><p>The pathophysiology of lichen planopilaris (LPP), a lymphocytic primary cicatricial alopecia, is largely unknown. We evaluated RNA expression of lesional scalp biopsies taken before and after 6 months of treatment monotherapy with oral hydroxychloroquine (HCQ), narrow band ultraviolet B (NB-UVB), or low level laser light therapy (LLLLT). <i>PTGER4</i> and <i>DOCK2</i> were significantly increased in all patients after treatment. <i>CYP1A2</i>, a drug metabolism enzyme, and <i>SSR2</i>, a gene involved in B cell activation and maturation, were increased posttreatment for the HCQ arm. <i>VEGFA</i>, which has been reported to be downregulated by phototherapy was decreased post NB-UVB treatment, while <i>SAA1</i>, an apolipoprotein gene present in plasma that is upregulated in response to tissue injury, was increased posttreatment for the NB-UVB arm. No significant differentially expressed genes (DEGs) in the LLLLT arm before and after treatment. The expressions of <i>CD68</i>, <i>COL5A1</i>, <i>MMP9</i>, <i>COL6A3</i>, and <i>CD44</i> were significantly higher at the baseline in biopsies from patients with a Lichen Planopilaris Activity Index (LPPAI) score ≥ 4 compared with those with an LPPAI < 4. These genes are involved in extracellular matrix organization and M2, or profibrotic, macrophage polarization, which is congruent with follicular scarring. Our data identify potential RNA biomarkers of LPPAI and suggest that M2 macrophages may play a role in LPP immunopathogenesis.</p>","PeriodicalId":11338,"journal":{"name":"Dermatology Research and Practice","volume":"2025 ","pages":"5545886"},"PeriodicalIF":1.5,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}